AJANTA PHARMA LTD
RESULTS FOR Q3 FY 2017-18
Q/E DECEMBER 2017
AJANTA PHARMA has declared its results for Q3 ended December 2017. The results are tabulated below :
| AJANTA PHARMA |
Dec '17 |
Sep '17 |
Jun '17 |
Mar '17 |
Dec '16 |
YOY |
QOQ |
| Net Sales |
587.05 |
540.38 |
473.12 |
456.12 |
515.02 |
13.99 |
8.64 |
| Other Operating Income |
-- |
-- |
-- |
20.69 |
18.09 |
|
|
| Total Income |
587.05 |
540.38 |
473.12 |
476.81 |
533.11 |
10.12 |
8.64 |
| EXPENDITURE |
|
|
|
|
|
|
| Raw Materials |
87.57 |
82.33 |
94.45 |
80.19 |
97.72 |
-10.39 |
6.36 |
| Traded Goods |
22.08 |
19.01 |
15.93 |
7.14 |
19.41 |
13.76 |
16.15 |
| Increase in Stocks |
0.34 |
7.69 |
-16.75 |
4.93 |
-10.71 |
-103.17 |
-95.58 |
| Employees Cost |
95.22 |
89.42 |
86.68 |
75.5 |
77.44 |
22.96 |
6.49 |
| Depreciation |
14.98 |
14.55 |
13.42 |
18.92 |
15.3 |
-2.09 |
2.96 |
| Other Expenses |
184.34 |
158.2 |
165.35 |
147.65 |
171.27 |
7.63 |
16.52 |
| P/L Before Other Inc., Int., Excpt. Items
& Tax |
182.52 |
169.18 |
114.04 |
142.48 |
162.68 |
12.2 |
7.89 |
| Other Income |
15.15 |
9.18 |
4.76 |
2.39 |
19.19 |
-21.05 |
65.03 |
| P/L Before Int., Excpt. Items & Tax |
197.67 |
178.36 |
118.8 |
144.87 |
181.87 |
8.69 |
10.83 |
| Interest |
0.14 |
0.09 |
0.07 |
0.89 |
0.82 |
-82.93 |
55.56 |
| P B T |
197.53 |
178.27 |
118.73 |
143.98 |
181.05 |
9.1 |
10.8 |
| Tax |
50.06 |
46.38 |
23.94 |
29.96 |
38.45 |
30.2 |
7.93 |
| Net Profit |
147.47 |
131.89 |
94.79 |
114.02 |
142.6 |
3.42 |
11.81 |
| Equity |
17.69 |
17.69 |
17.69 |
17.69 |
17.69 |
0 |
0 |
| Basic EPS |
16.76 |
14.99 |
10.77 |
12.96 |
16.21 |
3.39 |
11.81 |
| Diluted EPS |
16.75 |
14.98 |
10.77 |
12.95 |
16.2 |
3.4 |
11.82 |
| MP |
1495 |
|
|
|
|
|
|
| PE |
22.31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note : This does not constitute a BUY / SELL / HOLD recommendation
* * * E N D * * *
No comments:
Post a Comment